Valeant (VRX) Makes $5.7B Bid for Cephalon (CEPH)
Tweet Send to a Friend
Get Alerts VRX Hot Sheet
Up)
Trade VRX Now!
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) has made a $73 per share bid for Cephalon, Inc. (Nasdaq: CEPH).
Total value on the deal is $5.7 billion.
Valeant announced its intention to commence a consent solicitation process during the week of April 4th in an effort to replace Cephalon's current Board of Directors with its own nominees. Valeant anticipates that the transaction will be entirely debt financed.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Total value on the deal is $5.7 billion.
Valeant announced its intention to commence a consent solicitation process during the week of April 4th in an effort to replace Cephalon's current Board of Directors with its own nominees. Valeant anticipates that the transaction will be entirely debt financed.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Correct: Buying Warner Chilcott plc (WCRX) Seen as Takeover Defense by Actavis (ACT)
- Despite Outside Interest, Tumblr and Yahoo! (YHOO) Are in Lockup (MSFT) (FB)
- Compuware (CPWR), Elliott Extend Standstill Period by One Month
Create E-mail Alert Related Categories
Hot M&A, Mergers and Acquisitions, Trading Halts
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
